AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy. (March 2018)
- Record Type:
- Journal Article
- Title:
- AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy. (March 2018)
- Main Title:
- AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy
- Authors:
- Schindler, U.
Seitz, L.
Ashok, D.
Piovesan, D.
Tan, J.
DiRenzo, D.
Yin, F.
Leleti, M.
Rosen, B.
Miles, D.
Jin, L.
Park, T.
Young, S.
Soriano, F.
Rieger, A.
Karakunnel, J.
Sharif, E.
Powers, J.P.
Walters, M.J. - Abstract:
- Is Part Of:
- European journal of cancer. Volume 92(2018)Supplement 1
- Journal:
- European journal of cancer
- Issue:
- Volume 92(2018)Supplement 1
- Issue Display:
- Volume 92, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 92
- Issue:
- 1
- Issue Sort Value:
- 2018-0092-0001-0000
- Page Start:
- S14
- Page End:
- S15
- Publication Date:
- 2018-03
- Subjects:
- Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ejca.2018.01.037 ↗
- Languages:
- English
- ISSNs:
- 0959-8049
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 6202.xml